WuXi PharmaTech, the China-US CRO/CMO, paid $65 million in cash to acquire NextCODE Health, a genomic analysis and bioinformatics company with operations in the United States and Iceland. One year ago, NextCODE was spun out of deCODE Genetics with a five-year exclusive license to deCODE’s sequence-based clinical diagnostic applications. This acquisition involves WuXi in the clinical diagnostic market for the first time by identifying personalized regimens for individuals. The company says the transaction lays the groundwork for the creation of an integrated global enterprise for applying genomics to medicine.
Help employers find you! Check out all the jobs and post your resume.
